Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -62.39% is in line with its 3-year average of -56.85%, around the middle of its 3-year range (-76.20%–-33.61%).
38.23% below its 12-month average of -45.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -16.34%.
RETURN ON ASSETS (ROA)
-62.39%
RETURN ON ASSETS (ROA) AVG TTM
-45.13%
RETURN ON ASSETS (ROA) AVG 3Y
-56.85%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-38.23%
CURRENT VS 3Y AVG
-9.74%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-93.52%
vs the sector median at left
MapLight Therapeutics, Inc.
Market Cap
$412.48M
Return on Assets (ROA)
-62.39%
TTM Avg
-45.13%
3Y Avg
-56.85%
5Y Avg
N/A
Market Cap
$412.30M
Return on Assets (ROA)
12.09%
TTM Avg
1.03%
3Y Avg
-6.34%
5Y Avg
-7.45%
Market Cap
$414.70M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$419.61M
Return on Assets (ROA)
-61.86%
TTM Avg
-66.50%
3Y Avg
-24.17%
5Y Avg
-122.74%
Market Cap
$408.33M
Return on Assets (ROA)
-45.47%
TTM Avg
-26.84%
3Y Avg
-30.13%
5Y Avg
-31.02%
Market Cap
$406.92M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$404.51M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
Market Cap
$424.75M
Return on Assets (ROA)
-14.54%
TTM Avg
-48.52%
3Y Avg
-33.40%
5Y Avg
-26.00%
Market Cap
$403.00M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $412.48M | -62.39% | -45.13% | -56.85% | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $412.30M | 12.09% | 1.03% | -6.34% | -7.45% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.70M | -41.33% | -54.52% | -54.52% | -54.52% |
| Senseonics Holdings, Inc. (SENS)vs › | $419.61M | -61.86% | -66.50% | -24.17% | -122.74% |
| Neurogene Inc. (NGNE)vs › | $408.33M | -45.47% | -26.84% | -30.13% | -31.02% |
| Rezolute, Inc. (RZLT)vs › | $406.92M | -68.75% | -55.58% | -51.15% | -46.76% |
| Carlsmed, Inc. (CARL)vs › | $404.51M | -30.75% | -34.79% | -68.11% | -68.11% |
| Prothena Corporation plc (PRTA)vs › | $424.75M | -14.54% | -48.52% | -33.40% | -26.00% |
| Myriad Genetics, Inc. (MYGN)vs › | $403.00M | -17.62% | -32.09% | -24.12% | -19.05% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $401.34M | -71.16% | -43.23% | -31.68% | -18.72% |
ROA
-62.4%
ROE
-66.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -33.61% |
| 2024-12-31 | -56.66% |
| 2023-12-31 | -60.94% |
| 2022-12-31 | -76.20% |
